Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
11 2019
Historique:
received: 21 05 2019
revised: 08 08 2019
accepted: 09 08 2019
pubmed: 8 10 2019
medline: 7 7 2020
entrez: 8 10 2019
Statut: ppublish

Résumé

Early menopause is linked to an increased risk of cardiovascular disease mortality; however, the association between early menopause and incidence and timing of cardiovascular disease is unclear. We aimed to assess the associations between age at natural menopause and incidence and timing of cardiovascular disease. We harmonised and pooled individual-level data from 15 observational studies done across five countries and regions (Australia, Scandinavia, the USA, Japan, and the UK) between 1946 and 2013. Women who had reported their menopause status, age at natural menopause (if postmenopausal), and cardiovascular disease status (including coronary heart disease and stroke) were included. We excluded women who had hysterectomy or oophorectomy and women who did not report their age at menopause. The primary endpoint of this study was the occurrence of first non-fatal cardiovascular disease, defined as a composite outcome of incident coronary heart disease (including heart attack and angina) or stroke (including ischaemic stroke or haemorrhagic stroke). We used Cox proportional hazards models to estimate multivariate hazard ratios (HRs) and 95% CIs for the associations between age at menopause and incident cardiovascular disease event. We also adjusted the model to account for smoking status, menopausal hormone therapy status, body-mass index, and education levels. Age at natural menopause was categorised as premenopausal or perimenopausal, younger than 40 years (premature menopause), 40-44 years (early menopause), 45-49 years (relatively early), 50-51 years (reference category), 52-54 years (relatively late), and 55 years or older (late menopause). Overall, 301 438 women were included in our analysis. Of these 301 438 women, 12 962 (4·3%) had a first non-fatal cardiovascular disease event after menopause, of whom 9369 (3·1%) had coronary heart disease and 4338 (1·4%) had strokes. Compared with women who had menopause at age 50-51 years, the risk of cardiovascular disease was higher in women who had premature menopause (age <40 years; HR 1·55, 95% CI 1·38-1·73; p<0·0001), early menopause (age 40-44 years; 1·30, 1·22-1·39; p<0·0001), and relatively early menopause (age 45-49 years; 1·12, 1·07-1·18; p<0·0001), with a significantly reduced risk of cardiovascular disease following menopause after age 51 years (p<0·0001 for trend). The associations persisted in never smokers, and were strongest before age 60 years for women with premature menopause (HR 1·88, 1·62-2·20; p<0·0001) and early menopause (1·40, 1·27-1·54; p<0·0001), but were attenuated at age 60-69 years, with no significant association observed at age 70 years and older. Compared with women who had menopause at age 50-51 years, women with premature and early menopause had a substantially increased risk of a non-fatal cardiovascular disease event before the age of 60 years, but not after age 70 years. Women with earlier menopause need close monitoring in clinical practice, and age at menopause might also be considered as an important factor in risk stratification of cardiovascular disease for women. Australian National Health and Medical Research Council.

Sections du résumé

BACKGROUND
Early menopause is linked to an increased risk of cardiovascular disease mortality; however, the association between early menopause and incidence and timing of cardiovascular disease is unclear. We aimed to assess the associations between age at natural menopause and incidence and timing of cardiovascular disease.
METHODS
We harmonised and pooled individual-level data from 15 observational studies done across five countries and regions (Australia, Scandinavia, the USA, Japan, and the UK) between 1946 and 2013. Women who had reported their menopause status, age at natural menopause (if postmenopausal), and cardiovascular disease status (including coronary heart disease and stroke) were included. We excluded women who had hysterectomy or oophorectomy and women who did not report their age at menopause. The primary endpoint of this study was the occurrence of first non-fatal cardiovascular disease, defined as a composite outcome of incident coronary heart disease (including heart attack and angina) or stroke (including ischaemic stroke or haemorrhagic stroke). We used Cox proportional hazards models to estimate multivariate hazard ratios (HRs) and 95% CIs for the associations between age at menopause and incident cardiovascular disease event. We also adjusted the model to account for smoking status, menopausal hormone therapy status, body-mass index, and education levels. Age at natural menopause was categorised as premenopausal or perimenopausal, younger than 40 years (premature menopause), 40-44 years (early menopause), 45-49 years (relatively early), 50-51 years (reference category), 52-54 years (relatively late), and 55 years or older (late menopause).
FINDINGS
Overall, 301 438 women were included in our analysis. Of these 301 438 women, 12 962 (4·3%) had a first non-fatal cardiovascular disease event after menopause, of whom 9369 (3·1%) had coronary heart disease and 4338 (1·4%) had strokes. Compared with women who had menopause at age 50-51 years, the risk of cardiovascular disease was higher in women who had premature menopause (age <40 years; HR 1·55, 95% CI 1·38-1·73; p<0·0001), early menopause (age 40-44 years; 1·30, 1·22-1·39; p<0·0001), and relatively early menopause (age 45-49 years; 1·12, 1·07-1·18; p<0·0001), with a significantly reduced risk of cardiovascular disease following menopause after age 51 years (p<0·0001 for trend). The associations persisted in never smokers, and were strongest before age 60 years for women with premature menopause (HR 1·88, 1·62-2·20; p<0·0001) and early menopause (1·40, 1·27-1·54; p<0·0001), but were attenuated at age 60-69 years, with no significant association observed at age 70 years and older.
INTERPRETATION
Compared with women who had menopause at age 50-51 years, women with premature and early menopause had a substantially increased risk of a non-fatal cardiovascular disease event before the age of 60 years, but not after age 70 years. Women with earlier menopause need close monitoring in clinical practice, and age at menopause might also be considered as an important factor in risk stratification of cardiovascular disease for women.
FUNDING
Australian National Health and Medical Research Council.

Identifiants

pubmed: 31588031
pii: S2468-2667(19)30155-0
doi: 10.1016/S2468-2667(19)30155-0
pmc: PMC7118366
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e553-e564

Subventions

Organisme : British Heart Foundation
ID : RG/16/11/32334
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/2/30098
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : U01 AG012539
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012505
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY NC ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.

Références

BJOG. 2005 Apr;112(4):476-85
pubmed: 15777448
JAMA. 2002 Jul 17;288(3):321-33
pubmed: 12117397
Cochrane Database Syst Rev. 2015 Mar 10;(3):CD002229
pubmed: 25754617
J Am Coll Cardiol. 2009 Dec 15;54(25):2366-73
pubmed: 20082925
Lancet Neurol. 2012 Jan;11(1):82-91
pubmed: 22172623
Eur Heart J. 2011 Mar;32(6):745-50
pubmed: 21186237
JAMA Cardiol. 2016 Oct 1;1(7):767-776
pubmed: 27627190
Circulation. 2014 Apr 8;129(14):1493-501
pubmed: 24573351
BMC Public Health. 2014 Jan 08;14:9
pubmed: 24400870
Int J Epidemiol. 2013 Dec;42(6):1640-8
pubmed: 23143611
Arch Intern Med. 2008 Apr 28;168(8):861-6
pubmed: 18443262
Climacteric. 2017 Jun;20(3):187-194
pubmed: 28118068
Obstet Gynecol Clin North Am. 2011 Sep;38(3):425-40
pubmed: 21961711
Int J Epidemiol. 2005 Apr;34(2):251-6
pubmed: 15576467
Pharmacol Ther. 2012 Jul;135(1):54-70
pubmed: 22484805
J Korean Med Sci. 2005 Dec;20(6):1053-8
pubmed: 16361821
Hum Reprod. 2003 Jan;18(1):199-206
pubmed: 12525467
Eur J Epidemiol. 2018 Aug;33(8):699-710
pubmed: 29460096
Int J Epidemiol. 2017 Apr 1;46(2):e11
pubmed: 26430789
Menopause. 2014 Oct;21(10):1038-62
pubmed: 25225714
Int J Epidemiol. 2012 Feb;41(1):33-42
pubmed: 21044979
Ind Health. 2007 Oct;45(5):679-86
pubmed: 18057811
Int J Epidemiol. 2019 Aug 1;48(4):1275-1285
pubmed: 30796459
Int J Epidemiol. 2006 Feb;35(1):34-41
pubmed: 16155052
Climacteric. 2019 Aug;22(4):403-411
pubmed: 30829083
Maturitas. 1997 Jun;27(2):117-23
pubmed: 9255746
Int J Epidemiol. 2012 Oct;41(5):1241-7
pubmed: 21421694
Stroke. 2009 Apr;40(4):1044-9
pubmed: 19233935
Int J Cardiol. 2017 Aug 15;241:6-11
pubmed: 28392079
Maturitas. 2013 Mar;74(3):235-40
pubmed: 23313437
Circulation. 2005 Mar 15;111(10):1242-9
pubmed: 15769764
Int J Epidemiol. 2014 Oct;43(5):1542-62
pubmed: 24771324
Maturitas. 2006 Jan 20;53(2):226-33
pubmed: 15955642
Lancet. 1996 Mar 16;347(9003):714-8
pubmed: 8602000
Arch Intern Med. 1999 May 24;159(10):1061-6
pubmed: 10335682
Heart. 2016 Jan;102(1):63-8
pubmed: 26261158
J Pharmacol Exp Ther. 2015 Feb;352(2):291-304
pubmed: 25472954
Menopause. 2012 Oct;19(10):1081-7
pubmed: 22692332
Ann Endocrinol (Paris). 2003 Apr;64(2):87-92
pubmed: 12773939
Women Health. 2007;45(3):31-51
pubmed: 18032161
Int J Epidemiol. 2017 Apr 1;46(2):e8
pubmed: 26066328
Eur J Epidemiol. 2019 Mar;34(3):235-246
pubmed: 30721378
Menopause. 2011 Nov;18(11):1172-7
pubmed: 21775911
PLoS Med. 2018 Nov 27;15(11):e1002704
pubmed: 30481189
Am J Epidemiol. 2001 May 1;153(9):865-74
pubmed: 11323317
Lancet. 1998 May 9;351(9113):1425-7
pubmed: 9593428
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Maturitas. 2016 Oct;92:176-185
pubmed: 27621257
Am J Epidemiol. 2013 Jul 1;178(1):70-83
pubmed: 23788671
Int J Epidemiol. 2005 Oct;34(5):987-91
pubmed: 15894591
Menopause. 2010 May-Jun;17(3):506-10
pubmed: 20042893
Int J Epidemiol. 2017 Dec 1;46(6):1757-1757i
pubmed: 28641380
J Am Heart Assoc. 2017 Nov 2;6(11):
pubmed: 29097389
N Engl J Med. 1999 Jun 10;340(23):1801-11
pubmed: 10362825
Circulation. 2003 Oct 7;108(14):1688-93
pubmed: 12975257
Lancet. 2008 Mar 1;371(9614):760-70
pubmed: 18313505
Int J Epidemiol. 2006 Feb;35(1):49-54
pubmed: 16204333
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893

Auteurs

Dongshan Zhu (D)

School of Public Health, University of Queensland, Brisbane, QLD, Australia.

Hsin-Fang Chung (HF)

School of Public Health, University of Queensland, Brisbane, QLD, Australia.

Annette J Dobson (AJ)

School of Public Health, University of Queensland, Brisbane, QLD, Australia.

Nirmala Pandeya (N)

School of Public Health, University of Queensland, Brisbane, QLD, Australia; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Graham G Giles (GG)

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.

Fiona Bruinsma (F)

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.

Eric J Brunner (EJ)

Department of Epidemiology and Public Health, University College London, London, UK.

Diana Kuh (D)

Medical Research Council Unit for Lifelong Health and Ageing, University College London, London, UK.

Rebecca Hardy (R)

Medical Research Council Unit for Lifelong Health and Ageing, University College London, London, UK.

Nancy E Avis (NE)

Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Ellen B Gold (EB)

Department of Public Health Sciences, University of California, Davis School of Medicine, Davis, CA, USA.

Carol A Derby (CA)

Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY, USA.

Karen A Matthews (KA)

Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.

Janet E Cade (JE)

Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK.

Darren C Greenwood (DC)

Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK.

Panayotes Demakakos (P)

Department of Epidemiology and Public Health, University College London, London, UK.

Daniel E Brown (DE)

Department of Anthropology, University of Hawaii, Hilo, HI, USA.

Lynnette L Sievert (LL)

Department of Anthropology, University of Massachusetts Amherst, Amherst, MA, USA.

Debra Anderson (D)

Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.

Kunihiko Hayashi (K)

School of Health Sciences, Gunma University, Maebashi, Japan.

Jung Su Lee (JS)

Department of Public Health, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Hideki Mizunuma (H)

Fukushima Medical Center for Children and Women, Fukushima Medical University, Fukushima, Japan.

Therese Tillin (T)

Institute of Cardiovascular Science, University College London, London, UK.

Mette Kildevæld Simonsen (MK)

Parker Institute, Copenhagen University Hospital, Frederiksberg, Denmark; Aarhus University, Aarhus, Denmark.

Hans-Olov Adami (HO)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, Norway.

Elisabete Weiderpass (E)

International Agency for Research on Cancer, World Health Organization, Lyon, France.

Gita D Mishra (GD)

School of Public Health, University of Queensland, Brisbane, QLD, Australia. Electronic address: g.mishra@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH